The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Atrial fibrillation (AF) is the most common cause for an irregular heart beat. Catheter ablation is the only potential cure and involves passing wires via veins in the leg into the heart to deliver discrete small burns(ablation) around the pulmonary veins (PV), the major source for AF. Unfortunately 30-50% of patients have recurrent arrhythmia due to reestablishment of electrical connections. This multicentre internation trial examines whether more (maximal) ablation will improve the outcomes of ....Atrial fibrillation (AF) is the most common cause for an irregular heart beat. Catheter ablation is the only potential cure and involves passing wires via veins in the leg into the heart to deliver discrete small burns(ablation) around the pulmonary veins (PV), the major source for AF. Unfortunately 30-50% of patients have recurrent arrhythmia due to reestablishment of electrical connections. This multicentre internation trial examines whether more (maximal) ablation will improve the outcomes of the procedure.Read moreRead less
Remodelling In Cardiac Hypertrophy: Implications For Arrhythmogenesis
Funder
National Health and Medical Research Council
Funding Amount
$48,361.00
Summary
High blood pressure (HBP) affects 1 in 3 adults. Cardiac hypertrophy (thickened heart muscles) is a common condition seen in HBP. This research seeks to study the underlying changes in electrical, structural and molecular properties of the heart that may contribute to the increased sudden death and atrial fibrillation (irregular heart rhythm) associated with both HBP and cardiac hypertrophy. The new understanding may identify new treatment targets to reduce these life-threatening conditions.
Atrial Fibrillation And Hypertension: Reverse Cardiac Remodelling Post Renal Denervation
Funder
National Health and Medical Research Council
Funding Amount
$90,144.00
Summary
Patients with hypertension are at increased risk of heart rhythm disorders, yet little is known if treatment of high blood pressure will improve abnormal rhythm. Renal denervation is a new and effective treatment for severe hypertension; this study will assess the adverse changes in heart structure and function due to severe hypertension, and investigate whether renal denervation can ameliorate these changes on a structural and electrical level.
Genetic Predisposition To Abnormal Atrial Substrate In Atrial Fibrillation (GENE-AF Study)
Funder
National Health and Medical Research Council
Funding Amount
$100,531.00
Summary
Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide and its incidence is growing. Our world-first research aims to demonstrate that individuals who carry specific genetic variants are more likely to develop abnormal electrical and structural changes in the heart, which predispose to AF. In doing so, we intend to find the link between genetics and AF, paving the way for research into novel targeted therapies to better manage this complex and difficult to treat disease.
Development Of Endpoints For Catheter Ablation Of Non-mappable Scar-related Ventricular Tachycardia.
Funder
National Health and Medical Research Council
Funding Amount
$176,686.00
Summary
Ventricular tachycardia is a dangerous heart rhythm disturbance that affects people with scarring in the heart such as those with prior heart attacks or heart failure. Catheter ablation procedures, using wires passed from the groin, can be used to burn the short-circuits related to the scar. However in the majority of cases, it is very difficult to know when enough burning has been performed. This project aims to develop and validate several electrical and imaging endpoints for this procedure.
Exploring The Link Between Alcohol And Atrial Fibrillation Recurrence: A Multicentre Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Atrial fibrillation (AF) is the most common cardiac rhythm disturbance & is associated with a doubling in mortality (due to heart failure & stroke) and significant morbidity. Recent studies indicate that alcohol intake (even at mild-moderate levels) is a risk factor for AF. This world-first multicentre randomised controlled trial of 200 patients with AF aims to determine whether abstinence from alcohol (or significantly reduced consumption) will reduce frequency and burden of AF episodes.
Ryanodine Receptor Inhibitors As Therapy For Ca2+ Store Overload Induced Arrhythmias
Funder
National Health and Medical Research Council
Funding Amount
$555,892.00
Summary
This study investigates a new therapeutic action recently discovered for flecainide, an antiarrhythmic agent that we find to completely prevent and inherited form of stress-induced arrhythmias called CPVT. The findings will provide the first detailed mechanistic understanding of an antiarrhythmic drug, findings that will also give a new direction for drug design to control common arrhythmias such as occur in diseases such as coronary artery disease.
Preclinical Assessment Of Gene Therapy For Ventricular Arrhythmia
Funder
National Health and Medical Research Council
Funding Amount
$801,079.00
Summary
Up to 10% of patients are at risk of sudden death following myocardial infarction. Current treatment and preventative initiatives have their limits and are not without risk. In this proposal we will continue to develop an exciting new treatment approach using gene therapy technology. We will attempt to overcome some of the barriers for human application of this technology and pave the way for early phase clinical trials.